Jamjoom Pharmaceuticals Factory Co. · TADAWUL:4015
Jamjoom Pharmaceuticals Factory — H1 2025 Earnings Presentation
19 slides from Jamjoom Pharmaceuticals Factory's earnings presentation, Jul 24, 2025
Slide 1: Earnings Presentation 1H 2025
Earnings Presentation 1H 2025 Jeddah | 24 July 2025
Slide 2: Business and Strategy Highlights
Business and Strategy Highlights
Slide 3: Disclaimer
3 Disclaimer This presentation has been prepared solely for use as an investor presentation for Jamjoom Pharmaceuticals Factory Company (the “Company”). By attending or by reading this presentation, you agree to be bound by the following limitations. The information contained in this presentation is
Slide 4: 1H 2025 Highlights: Highest ever 1st half revenue and profitability
4 Business and Strategy Highlights 1H 2025 Highlights: Highest ever 1st half revenue and profitability Revenue # of Brands 3 new launches Underpinned by successful execution of our +1 in Anti-Diabetic 1H 25 +17% YoY market penetration strategy across key 1H 25 +3 YTD +1 in Ophthalmology SAR therapeu
Slide 5: Translating strategy into tangible results - 1H 2025
5 Business and Strategy Highlights Translating strategy into tangible results - 1H 2025 • As per IQVIA, KSA retail market1 grew +13% (JP grew +18%) Saudi Market • Successful execution of commercial strategy to further bolster market share growth in home market • Significant growth in institutional s
Slide 6: Focus on strategic brands and core markets fuels revenue growth
6 Business and Strategy Highlights Focus on strategic brands and core markets fuels revenue growth Revenue Contribution by Therapeutic Area, YoY (SARmn) Revenue Contribution by Country, YoY (SARmn) +17% 99 17 18 854 731 (5) (6) +17% Institutional sales Adverse geopolitical Growth +13% in EGP up 90%
Slide 7: Monthly revenue growth for top KSA pharma since Jan '22
7 Business and Strategy Highlights Monthly revenue growth1 for top 5 KSA pharma since Jan ’22 (41 months) Peer 1 17 negative months Peer 2 7 negative months 2 negative months Peer 3 16 negative months Peer 4 18 negative months Jan-22 Jul-22 Jan-23 Jul-23 Jan-24 Jul-24 Jan-25 May-25 IQVIA Analysis 20
Slide 8: Therapeutic mix diversification underpins long-term growth trajectory
8 Business and Strategy Highlights Therapeutic mix diversification underpins long-term growth trajectory 2021 Revenue Contribution by Therapeutic Area (SARmn) 1H 2025 Revenue Contribution by Therapeutic Area (SARmn) Anti-diabetic Pain & Inflammation Pain & Inflammation 2% 5% C. Nervous System 6% 2%
Slide 9: Successfully transitioning to multiple sites to support expansion
9 Business and Strategy Highlights Successfully transitioning to multiple sites to support expansion SAR 100bn+ of Total Addressable Market in Jeddah Jeddah Cairo Algiers* Core Geographies By 2027 Main Facility Sterile Facility Main Facility Facility Iraq Kuwait Bahrain Egypt Qatar Kingdom of Saudi
Slide 10: Robust R&D pipeline and BD strategy driving long-term value creation
10 Business and Strategy Highlights Robust R&D pipeline and BD strategy driving long-term value creation Under SFDA review Ready for SFDA Submission Under Development Total 2 Ophthalmology 9 16 5 3 General Medicine 3 Dermatology Revenue growth EBITDA2 4 2 margin 2 Gastrointestinal 3 6 1 1 Cardiovasc
Slide 11: Strategic BD partnerships support regional leadership ambitions
11 Business and Strategy Highlights Strategic BD partnerships support regional leadership ambitions Selected key agreements signed # Partner Product Type Therapeutic Area Coverage Model 1 Swiss Specialty Pharma Biosimilar Cardiometabolic MENA License and supply with potential localization 2 EU Pharm
Slide 12: Financial Highlights
Financial Highlights
Slide 13: 2nd Quarter 2025 highlights: Delivering another quarter of healthy margins
13 Financial Highlights 2nd Quarter 2025 highlights: Delivering another quarter of healthy margins Revenue (SARmn) EBITDA (SARmn) +27% +15% 148 396 346 117 EBITDA Margin 33.8% 37.5% 2Q 24 2Q 25 2Q 24 2Q 25 Gross Profit (SARmn) Net Profit (SARmn) +15% +23% 251 132 218 107 driven by high-margin strate
Slide 14: Operational efficiency to curtail rising operating costs
14 Financial Highlights Operational efficiency to curtail rising operating costs … Total Cost Of Revenue Movement YoY (SARmn) Operating Expenses Movement YoY (SARmn) +18% 5 310 11 3 +9% 27 229 3 6 12 250 264 Maintained S&D/Sales down G&A/Sales up R&D/Sales YoY 3ppts YoY 0.8 ppts YoY +18% +3% +37% 1H
Slide 15: … and deliver highest ever 1H margins in JP's history
15 Financial Highlights … and deliver highest ever 1H margins in JP’s history EBITDA Movement YoY (SARmn) Quarterly Trend of Profitability (%) +27% 63.1% 64.0% 63.3% 123 EBITDA Margin 61.0% 37.6% 59.3% 9 321 EBITDA Margin 34.7% (46) (6) (12) 253 37.7% 37.5% 33.8% 34.1% 34.3% 27.7% Successful operati
Slide 16: Optimizing cash conversion cycle to fuel commercial momentum
16 Financial Highlights Optimizing cash conversion cycle to fuel commercial momentum ▪ Cash conversion cycle extended to 305 days reflecting a 12.5% YoY increase (~16% Cash Conversion Cycle (Days) CAGR) to support revenue growth, ensuring inventory availability, higher institutional sales, and suppl
Slide 17: Outlook and Guidance
Jamjoom Pharma LojLé pgaa Outlook and Guidance
Slide 18: Financial guidance: Strong momentum towards achieving upgraded targets
18 Outlook and Guidance Financial guidance: Strong momentum towards achieving upgraded targets FY 25 Guidance (Initial) FY 25 Guidance (Updated) 1H 25 Actual Performance Revenue growth 12-15% 12-15% 16.8% EBITDA margin (Upgraded) 30-31.5% 31.5-33% 37.6% CAPEX 4-6% 4-6% 4.7% SAR 2.00 per share announ
Slide 19: Q&A
Q&A Tarek Hosni, Chief Executive Officer Anwer Mohiuddin, Chief Financial Officer Muhammad Bin Khalid, Assoc. Director – Finance & IR
Jamjoom Pharmaceuticals Factory — H1 2025 Earnings Presentation on 6ix